Holen Sie sich die Stockscreener-App
29.37
0.44%
0.13
Schlusskurs vom Vortag:
$29.24
Offen:
$29.38
24-Stunden-Volumen:
388.64K
Relative Volume:
0.73
Marktkapitalisierung:
$1.45B
Einnahmen:
$447.57M
Nettoeinkommen (Verlust:
$-38.92M
KGV:
-35.39
EPS:
-0.83
Netto-Cashflow:
$-1.15M
1W Leistung:
-3.83%
1M Leistung:
-6.46%
6M Leistung:
-25.65%
1J Leistung:
+23.30%
1-Tages-Spanne:
$29.23
$30.01
1-Wochen-Bereich:
$28.96
$30.69
52-Wochen-Spanne:
$20.20
$43.11
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Vergleichen Sie ATRC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
29.37 | 1.51B | 447.57M | -38.92M | -1.15M | -0.83 |
|
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
What drives AtriCure Inc. stock priceRapid profit acceleration - jammulinksnews.com
What analysts say about AtriCure Inc. stockExceptional profit margins - jammulinksnews.com
Is AtriCure Inc. a good long term investmentDynamic investment opportunities - jammulinksnews.com
AtriCure Inc. Stock Analysis and ForecastFree Stock Market Trend Analysis - Autocar Professional
Left Atrial Appendage Closure (LAAC) Device Market Key Players, Share and Forecast Outlook - openPR.com
AtriCure Shares Plunge 1.65% Amid FDA Approval Concerns - AInvest
AtriCure Inc. (ATRC) shares plunge 2.07% to lowest since May 2025 - AInvest
AtriCure Inc. (ATRC) Drops 2.94% in Two Days, Hits 2025 Low - AInvest
AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention - BioSpace
Why AtriCure Inc. stock attracts strong analyst attentionMarket Timing Advice - Newser
Why RadNet Inc. stock attracts strong analyst attentionReal Time Alert Service - Newser
How AtriCure Inc. stock performs during market volatilityFree Predictions - Newser
AtriCure completes enrollment in landmark cardiac stroke prevention trial By Investing.com - Investing.com Canada
AtriCure completes enrollment in landmark cardiac stroke prevention trial - Investing.com Australia
What makes AtriCure Inc. stock price move sharplyRisk Adjusted Stock Signals - Newser
AtriCure, Inc. (ATRC) Stock Analysis: Unveiling a 59% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
AtriCure completes enrollment in stroke prevention trial - MassDevice
Left Atrial Appendage Closure Devices Market Exclusive Report - openPR.com
(ATRC) On The My Stocks Page - news.stocktradersdaily.com
AtriCure Data Breach Investigation - Claim Depot
Artivion Inc. Data Breach Affects 5,608 in Texas: SSNs Exposed - Claim Depot
AtriCure (NASDAQ:ATRC) Has Debt But No Earnings; Should You Worry? - simplywall.st
AtriCure to Announce Second Quarter 2025 Financial Results - The Globe and Mail
AtriCure, Inc. (NASDAQ:ATRC) Receives Consensus Rating of “Buy” from Analysts - Defense World
AtriCure, Inc.(NasdaqGM: ATRC) dropped from Russell 3000E Value Index - MarketScreener
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
AtriCure: Profits And Operating Leverage Are Needed Here (NASDAQ:ATRC) - Seeking Alpha
Cryoablation Probe Market Size, Share | Industry Report 2030 - Grand View Research
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year? - Yahoo Finance
Transcript : AtriCure, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 04 - MarketScreener
AtriCure at Goldman Sachs Conference: Strategic Growth Insights - Investing.com India
AtriCure at Goldman Sachs Conference: Strategic Growth Insights By Investing.com - Investing.com UK
AtriCure's Strategic Momentum: Leadership in Atrial Fibrillation Management Takes Center Stage - AInvest
Ameriprise Financial Inc. Invests $295,000 in AtriCure, Inc. (NASDAQ:ATRC) - Defense World
Global Cardiac Ablation Market: Advancements in Minimally Invasive Procedures and 13% CAGR by 2030 - PharmiWeb.com
Left Atrial Appendage Closure Device Market projected to surpass US$ 8,786.032 million by 2030 at a CAGR of - EIN News
AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Jane Street Group LLC - Defense World
AtriCure (NASDAQ:ATRC) Downgraded to “Hold” Rating by Wall Street Zen - Defense World
(ATRC) Investment Analysis - news.stocktradersdaily.com
AtriCure’s chief scientific officer sells $83,600 in stock By Investing.com - Investing.com India
Insider Sell: Vinayak Doraiswamy Sells 2,500 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure’s chief scientific officer sells $83,600 in stock - Investing.com Australia
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):